FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Exenatide (BYDUREON) Extended Release for Injectable Suspension
Status: Discontinuation
»Therapeutic Categories: Endocrinology/Metabolism

AstraZeneca (New 04/03/2018)

Company Contact Information:
800-236-9933

Presentation Posting Date Related Information
BYDUREON® (exenatide extended-release) for injectable suspension, for subcutaneous use; Single Dose Tray presentation; (2 mg) (NDC 0310-6520-04) 04/03/2018 The planned permanent discontinuance of the Bydureon Single Dose Tray inventory from the U.S. market is September 30, 2018. There are currently 2 other delivery options for exenatide-extended-release: the Bydureon® Dual Chamber Pen presentation (NDC 0310-6530-04) and Bydureon® BCise™ (NDC 0310-6540-04).

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English